Send to

Choose Destination
Int J Cancer. 2018 Dec 1;143(11):2985-2996. doi: 10.1002/ijc.31864. Epub 2018 Oct 4.

Ligand-activated interaction of PPARδ with c-Myc governs the tumorigenicity of breast cancer.

Author information

Sanghuh College of Life Sciences, Konkuk University, Seoul, South Korea.
Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston.
Department of Nursing, Semyung University, Jechon, South Korea.


Peroxisome proliferator-activated receptor (PPAR) δ is a promising therapeutic target in metabolic and inflammatory disorders. However, its role in oncogenesis is controversial, and its therapeutic potential remains to be determined. In our study, we show that ligand-activated PPARδ forms a complex with the proto-oncogene product c-Myc. The interaction of PPARδ with c-Myc affected the transcriptional activity of c-Myc and the expression of its target genes. The PPARδ-dependent regulation of c-Myc activity was associated with decreased tumorigenicity in breast cancer cells. Administration of the PPARδ ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARδ, but not those expressing dominant-negative PPARδ, by interfering with c-Myc function through protein-protein interaction. Our results indicating that PPARδ forms an antitumorigenic complex with c-Myc in the presence of ligand suggest a potential role of PPARδ in breast cancer development.


PPARδ; breast cancer; c-Myc; protein-protein interaction; tumorigenicity

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center